Therapeutic and Technology Areas of Interest

Takeda sets several prioritized disease areas for research and development, i.e., metabolic / cardiovascular diseases, cancer and urological diseases, central nervous system diseases, and gastrointestinal diseases. Specifically, we target our licensing activities at the following therapeutic areas.

• Metabolic/cardiovascular diseases

Diabetes mellitus and its complications, hyperlipidemia, obesity, hypertension, thrombosis, and congestive heart failure

• Cancer and urological diseases

Solid tumors, blood malignancies, adjuvant therapies for cancer, urination disorders, neurogenic bladder, and endometriosis

• Central nervous system diseases (including skeletal and joint diseases)

Depression, schizophrenia, anxiety disorders, insomnia, migraine, Alzheimer's disease, Parkinson's disease, various pain types, osteoporosis, arthritis, and osteoarthrosis

• Gastrointestinal diseases and other disease areas

Gastrointestinal diseases such as gastroesophageal reflux disease, functional gastrointestinal disease, irritable bowel syndrome, Crohn's disease, and ulcerative colitis and respiratory diseases such as chronic obstructive pulmonary disease, asthma, and rhinitis

It aims to create drugs based on new technologies such as antibody and nucleic acid preparations, which are biological preparations, as well as tablets, injections, and vaccines.
In addition, we have keen interests in various discovery research technologies and original drug development concepts and approaches, which are indispensable for improving the efficiency of research and development of new drugs.